Register

Facharzt FMH Medizinische Onkologie Practice Questions - Facharzt FMH Für Medizinische Onkologie Spécialiste FMH En Oncologie Médicale Exam

Access More Questions
A 62-year-old woman with metastatic ER-positive, HER2-low (IHC 1+, ISH-negative) breast cancer develops symptomatic bone and visceral liver metastases after progressing through two prior lines of endocrine therapy plus CDK4/6 inhibition and one line of single-agent paclitaxel chemotherapy. Her ECOG performance status is 1. Which systemic therapy is supported by Phase III trial data (DESTINY-Breast04) to provide statistically significant progression-free and overall survival benefits in this setting?
Correct Answer:
Trastuzumab deruxtecan (T-DXd)

Access more questions from this quiz

Continue to Facharzt FMH Medizinische Onkologie Practice Questions - Facharzt FMH für Medizinische Onkologie Spécialiste FMH en oncologie médicale Exam for more practice questions and the full quiz experience.

Access More Questions